Seeing Is Believing

Currently out of the existing stock ratings of Steve Chesney, 20 are a BUY (41.67%), 6 are a SELL (12.5%), 22 are a HOLD (45.83%).
Analyst Steve Chesney, currently employed at REDBURN, carries an average stock price target met ratio of 68.75% that have a potential upside of 28.53% achieved within 513 days.
Steve Chesney’s has documented 94 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 06-Feb-2024.
Analyst best performing recommendations are on CELG (CELGENE).
The best stock recommendation documented was for CELG (CELGENE) at 12/18/2015. The price target of $122 was fulfilled within 5 days with a profit of $11.86 (10.77%) receiving and performance score of 21.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 20-Feb-2026
$185
$-6.82 (-3.56%)
9 days ago
(20-Feb-2026)
7/9 (77.78%)
$-7.08 (-3.69%)
393
Hold Since 22-May-2019
$187
$-4.82 (-2.51%)
$121
19 days ago
(10-Feb-2026)
27/31 (87.1%)
$-1.99 (-1.05%)
183
Buy Since 03-Mar-2022
$233
$41.18 (21.47%)
$210
20 days ago
(09-Feb-2026)
39/74 (52.7%)
$39.19 (20.22%)
121
Buy Since 01-May-2023
$246
$54.18 (28.25%)
$165
20 days ago
(09-Feb-2026)
12/15 (80%)
$52.19 (26.93%)
319
Buy Since 27-Jan-2020
$230
$38.18 (19.90%)
$220
20 days ago
(09-Feb-2026)
14/28 (50%)
$36.19 (18.67%)
228
What Year was the first public recommendation made by Steve Chesney?